Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC
Fruit of the collaboration between the National Institute for Research in Digital Science and Technology (INRIA) and the PIONeeR consortium, the QUANTIC project aims to generate dense longitudinal data in lung cancer patients undergoing anti-PD1/PDL1 therapy. The primary objective of QUANTIC is to develop and validate a mechanistic dynamic model of response and resistance to immune-checkpoint inhibition, leveraging the unique, large scale, multi-modal and longitudinal data collected during the randomized PIONeeR clinical study. A better understanding of these mechanisms should help identifying actionable items to increase the efficacy of immune-checkpoint inhibitors.
This unique framework is detailed by Pr. Joseph Ciccolini (AMU, AP-HM, CRCM), Dr. Sébastien Benzekry (INRIA) and Pr. Fabrice Barlesi (AMU, IGR, Marseille Immunopole) in the British Journal of Cancer (June 16, 2020).